Publications by authors named "Miguel Bajouco"
Article Synopsis
- Diagnosing psychotic disorders lacks sufficient molecular support, despite various research efforts focusing on different aspects of these conditions.
- The study utilized SWATH-MS proteomics on blood samples from first-episode psychosis patients and controls, identifying 389 proteins significant for distinguishing between the two groups.
- The findings emphasize the value of combining protein- and peptide-level analyses to uncover potential biomarkers for early detection of conditions like schizophrenia, suggesting that post-translational modifications of proteins may provide essential diagnostic insights.
Cariprazine is an atypical antipsychotic that has D2 and D3 partial agonism properties in addition to the usual 5-HT2A receptor antagonist action of second-generation antipsychotics. It has a distinctly higher affinity for D3 receptors, which is 10-fold higher than for D2 receptors. Cariprazine is also a 5-HT1A partial agonist, with a potential antidepressant effect.
View Article and Find Full Text PDFAim: Patients in early phases of schizophrenia or mood disorders with psychotic symptoms have a wide array of metabolic abnormalities. We analysed the potential predictive value of uric acid (UA) levels and other metabolic parameters in first-episode psychosis patients to differentiate between non-affective and affective psychosis.
Methods: Retrospective chart review of all patients referenced to a first-episode psychosis unit (n = 149), between 2012 and 2017, with available UA levels.
Antipsychotic medication non-adherence is a complex and multifaceted problem that may hinder recovery in psychosis-spectrum disorders. Therefore, it warrants an early and comprehensive assessment. Current self-report measures focus entirely on behavioral and attitudinal barriers to adherence, failing to provide insight about key psychosocial drivers such as shame and stigma that may also account for non-adherence.
View Article and Find Full Text PDF